Contineum Therapeutics, Inc. (CTNM)
(Delayed Data from NSDQ)
$20.77 USD
-0.23 (-1.10%)
Updated Jul 12, 2024 04:00 PM ET
After-Market: $20.60 -0.17 (-0.82%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth A Momentum D VGM
Price, Consensus and EPS Surprise
CTNM 20.77 -0.23(-1.10%)
Will CTNM be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for CTNM based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Other News for CTNM
Contineum Therapeutics Announces Appointment of Sarah Boyce to Board of Directors
Contineum Therapeutics Welcomes Sarah Boyce to Board
Contineum: LPA1R Antagonist Drug Advancement Against IPF With Proven Track Model
Contineum Therapeutics to Present at the 45th Annual Goldman Sachs Healthcare Conference
Contineum Therapeutics Announces Appointment of John Healy as General Counsel & Corporate Secretary